MLYS Mineralys TherapeuticsWatchlist
About Mineralys Therapeutics Company
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Mineralys Therapeutics(MLYS.US) Officer Buys US$25,355.93 in Common Stocks
$Mineralys Therapeutics(MLYS.US)$ Officer Congleton Jon purchased 4,250 shares of Common Stocks on Nov 22, 2023 at an average price of $5.9661 for a total value of $25,355.93.Source: Announcement What
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript